ASX stock of the day: This ASX healthcare share jumped 13% today as it commenced trials of its COVID-19 treatment

Shares in Mesoblast Limited (ASX: MSB) are up more than 13% today after the healthcare company announced the first patients had been dosed in a trial of its COVID-19 treatment.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price is up more than 13% today after the healthcare company announced the first patients had been dosed in a trial of its COVID-19 treatment. The Phase 2/3 trial is taking place in the United States to test Mesoblast's remestemcel-L treatment. 

Who is Mesoblast?

Mesoblast develops allogeneic (off-the-shelf) cellular medicines to treat inflammatory diseases. The company has leveraged its proprietary mesenchymal cell therapy technology to establish a broad portfolio of commercial products and late-stage product candidates. Mesenchymal stem cells can differentiate into a variety of cell types including bone, cartridge, and muscle cells. 

What is the treatment?

Mesoblast's remestemcel-L medicine is being used to treat COVID-19 infected patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilator support. Promising results were received under an initial trial of the treatment at Mount Sinai Hospital in New York. 

Remestemcel-L is being developed for various inflammatory conditions, including acute graft versus host disease. It is believed to counteract inflammatory processes by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of anti-inflammatory cells to involved tissues. 

Clinical trials

Mesoblast is conducting a clinical trial of remestemcel-L with 300 ventilator-dependent patients in intensive care. Patients will receive either remestemcel-L or a placebo, on top of maximal care. The efficacy of the treatment will be assessed according to survival rates and the number of days alive and off medical support. 

The trial will take place at 30 sites across North America. Enrollment in the trial is expected to be completed within 3 to 4 months. Interim analyses are planned which could result in stopping the trial early. 

Dr Moskowitz, who is overseeing the trial, said, "this rapid mobilization of major medical centres across the United States reflects the urgent need to treat the very large numbers of people in hospital intensive care units suffering with COVID-19 ARDS and requiring ventilation. We expect quick enrollment in this trial to determine whether remestemcel-L can reduce mortality in these patients."

Foolish takeaway

Mesoblast has an early prospect for treating COVID-19 which could prove lucrative if clinical trials are successful. On the back of key announcements relating to this trial, the Mesoblast share price has rocketed 167% higher since the beginning of April.

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »